Search

Your search keyword '"Giannetto V"' showing total 5 results
Start Over Author "Giannetto V"
5 results on '"Giannetto V"'

1. Secondary Hyperparathyroidism and renal transplantation

Author

GIOVIALE, Maria Concetta, LO MONTE, Attilio Ignazio, MOSCATO, Francesco, ROMANO, Giorgio, BUSCEMI, Giuseppe, ROMANO, Maurizio, MAIONE C, BUSCEMI B, GIANNETTO V, GIOVIALE MC, LO MONTE AI, MAIONE C, MOSCATO F, ROMANO G, BUSCEMI B, GIANNETTO V, BUSCEMI G, and ROMANO M

Published
2007

2. Secondary Hyperparathyroidism and renal tranplantation

Author

MAIONE C, MOSCATO, Francesco, ROMANO G, BUSCEMI B, GIANNETTO V, GIOVIALE, Maria Concetta, ROMANO, Maurizio, GIOVIALE MC, LO MONTE AI, MAIONE C, MOSCATO F, ROMANO G, BUSCEMI B, GIANNETTO V, BUSCEMI G, and ROMANO M

Published
2007

4. Platelet thromboxane formation and BTG levels after intensive charcoal HP in uremics or regular hemodialytic treatment (RHT).

Author

Capodicasa G, Daví G, Picone F, Mattina A, Giannetto V, Vinti V, Vaccaro F, Strano A, De Santo NG, and Giordano C

Subjects
Adult, Charcoal, Humans, Middle Aged, Thromboxane B2 biosynthesis, Beta-Globulins blood, Blood Platelets metabolism, Hemoperfusion, Kidney Failure, Chronic blood, Renal Dialysis, Thromboxanes biosynthesis, Uremia blood, beta-Thromboglobulin blood
Abstract

Vascular tissues from uremic patients show increased prostaglandin synthesizing capacity while uremic platelets have decreased thromboxane synthesis. It has been suggested that the platelet defects in uremia are partially corrected by hemodialysis and a correlation with the levels of guanidinsuccinic acid, phenolic acid, creatinine or urea has been demonstrated. In our study 6 patients with end-stage renal disease on RHT, underwent, daily and for ten days, two-hours hemoperfusion, in order to obtain lower levels of toxic metabolites such as creatinine (less than 6 mg/dl.). Before and after this intensive treatment we have evaluated BTG plasmatic levels and thromboxane formation by platelets after thrombin and arachidonic acid stimulation. The thromboxane formation was not increased following this treatment, whereas BTG plasmatic levels were significantly diminished.

Published
1983

5. Clinical effectiveness of apheresis in the treatment of progressive systemic sclerosis.

Author

Capodicasa G, De Santo NG, Galione A, Vinti V, Giannetto V, Annaloro R, Vaccaro F, Bellavia C, Picone F, and Riccobene G

Subjects
Adult, Antibodies analysis, Antigen-Antibody Complex analysis, Female, Humans, Immunoglobulins analysis, Scleroderma, Systemic immunology, T-Lymphocytes classification, Plasma Exchange, Scleroderma, Systemic therapy
Abstract

Scleroderma is a chronic disease of unknown origin characterized by diffuse sclerosis of the connective tissue of the integument and other organs. As in systemic lupus erythematosus (SLE), rheumatoid arthritis and dermatomyositis, a variety of antibodies may be found in the serum, suggesting that immune mechanisms may be involved. In two uremic patients with scleroderma, the effects were studied of the removal, by pheresis, of antinuclear antibodies, immune complexes, and immunoglobulin factors perpetuating the inflammatory response. We used a membrane plasmapheresis with a hollow-fiber type plasmafilter (Plasmaflo, Asahi) connected online with a hemofilter for conventional dialysis. The aim of this preliminary study was to induce a remission of the edematous inflammatory phase. The correlation of a improvement in clinical response and a decrease in the levels of immune complexes or other factors of inflammation was observed. In our view membrane-plasmapheresis is a process safely carried out by the hemodialysis staff and it may be of clinical effectiveness, especially, in patients with life-threatening complications of progressive systemic sclerosis.

Published
1983

Catalog

Books, media, physical & digital resources
See catalog results